Vaccines/Biological Products Panel Meets 3/4

Federal Register notice: FDA has announced a 3/4 Vaccines and Related Biological Products Advisory Committee meeting. Panel members will discuss and make recommendations on the selection of strains to be included in the influenza virus vaccines for the 2020 to 2021 flu season. Also, they will hear an overview of research programs from ongoing in CBER’s Laboratory of Respiratory and Special Pathogens division. To view the notice, click here.

Read more